Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2019-11-11 AGM Information
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
NEW DATA ON FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) DEMONSTRATE DURABLE EFFICACY AND SAFETY PROFILE
AGM Information Classification · 95% confidence The document is a press release from Gilead Sciences and Galapagos NV announcing detailed results from their clinical trial program for filgotinib in Rheumatoid Arthritis (RA). Key phrases include 'Data worden gepresenteerd op jaarvergadering 2019 van ACR/ARP' (Data will be presented at the 2019 ACR/ARP annual meeting) and the content details clinical efficacy and safety data (Abstracts #517, #504, #1329, #2875, #550). This content is typical of an announcement related to clinical trial data being presented at a major medical conference, which often accompanies or precedes a formal Investor Presentation (IP) or is released as a general press announcement. Since it is a detailed announcement of study results and not a formal regulatory filing (like 10-K) or a transcript of a call, and it focuses heavily on presenting scientific data to investors/the public, 'Investor Presentation' (IP) is the most fitting category, although 'Earnings Release' (ER) or 'Regulatory Filing' (RNS) could be considered. Given the focus on presenting detailed clinical data abstracts, IP is superior to ER (which is usually just financial highlights) and RNS (which is a fallback). The document is a comprehensive announcement of data, not just a notice that a report is available (which would be RPA).
2019-11-11 Dutch
NEW DATA ON FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) DEMONSTRATE DURABLE EFFICACY AND SAFETY PROFILE
Earnings Release Classification · 99% confidence The document is a press release dated November 9, 2019, announcing detailed results from the FINCH RA clinical program for the drug filgotinib, with data to be presented at the 2019 ACR/ARP Annual Meeting. It details efficacy and safety data from Phase 3 trials (FINCH 1, 2, 3) and long-term extension data (DARWIN 3). This content structure—announcing clinical trial results and upcoming presentation dates—is characteristic of an Earnings Release (ER) or a general press announcement related to clinical progress. Since it is a detailed announcement of financial/clinical performance highlights rather than a full, comprehensive report (like a 10-K or IR), and it is not a transcript (CT) or a formal proxy/governance document, the most fitting category is Earnings Release (ER), as these announcements often coincide with reporting periods or major data readouts. It is not a Report Publication Announcement (RPA) because it contains the substantive data itself, not just a notice that a report is available. Q4 2019
2019-11-11 English
Galapagos increases share capital through warrant exercise by Gilead
Share Issue/Capital Change Classification · 99% confidence The document is a press release from Galapagos NV announcing a capital increase resulting from the exercise of a warrant by Gilead. Key phrases include 'kapitaalverhoging' (capital increase), 'uitoefening van een warrant' (exercise of a warrant), and details about the number of new shares issued and the resulting changes to the company's share capital and voting rights ('maatschappelijk kapitaal', 'stemrechtverlenende effecten'). This directly relates to changes in the company's financing and capital structure. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (4241 chars) is substantial enough to be the primary announcement, not just a brief RPA.
2019-11-07 Dutch
Galapagos increases share capital through warrant exercise by Gilead
Share Issue/Capital Change Classification · 98% confidence The document explicitly announces an increase in share capital resulting from the exercise of warrants by Gilead. Key phrases include 'share capital increase arising from a warrant exercise' and details about the subscription of new shares. This directly relates to changes in the company's capital structure and financing activities. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). The document length (3832 chars) is substantial enough to be the primary announcement, not just a brief RPA.
2019-11-07 English
PR Gilead warrant exercise FINAL.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document explicitly announces an increase in share capital due to the exercise of warrants by Gilead. This action directly relates to changes in the company's capital structure and the issuance of new shares. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although it involves share issuance, the primary focus is the financing/capital structure event (warrant exercise leading to new shares) rather than a general share repurchase (POS) or a broad capital change announcement (SHA), making CAP the most precise fit for this specific financing transaction.
2019-11-06 English
PR Gilead warrant exercise NL FINAL.docx.pdf
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces a capital increase ('kapitaalverhoging') resulting from the exercise of warrants by Gilead. It details the number of new shares issued, the price per share, and the resulting change in the company's share capital and total voting rights. This content directly relates to changes in the company's capital structure and financing activities. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not an earnings release (ER), an annual report (10-K), or a general regulatory filing (RNS), as it concerns a specific corporate finance event.
2019-11-06 Dutch

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.